ArticleMediators of inflammation2025
Velutin Inhibits IL-1β-Induced Nucleus Pulposus Inflammatory and Extracellular Matrix Degradation Attenuating Mouse Intervertebral Disc Degeneration via the NF-κB and MAPK Pathways.
Article in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Process Optimization and Flavor Analysis ofFoods (Basel, Switzerland) · 2026Article
- Targeting the nuclear factor kappa B pathway for the medical management of intervertebral disc degeneration.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disk degeneration (IVDD) usually causes lower back pain (LBP). Mechanical stress, trauma, aseptic inflammation, infection, and genetic susceptibility can accelerate the development of IVDD. Reportedly, proinflammatory cytokines and extracellular matrix (ECM) degradation play significant roles in IVDD progression. Therefore, anti-inflammatory treatments and ECM inhibition can potentially delay the progression of IVDD. Velutin, a natural flavonoid, has the vigorous effects of suppressing inflammation. In this study, we researched the protective effects of velutin and the underlying mechanisms. Additionally, we evaluated its validity in a mouse IVDD model. The results indicated that velutin effectively suppressed interleukin-1β-induced inflammatory mediators. Moreover, our findings revealed the mechanisms of velutin's anti-inflammatory effects. Our results indicate that velutin is a potential therapeutic agent for IVDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.